HLA-DRA has emerged as a key target in immunotherapy, previously associated with an inflamed TME in tumors and various non-tumor diseases, including COVID-19, osteoarthritis, and dry eye syndrome (43, 55–57). Here, HLA-DRA is linked to dry eye syndrome.